Special Issue Introduction
Proposed Articles The Dynamic State of Lymphoma Care. 1. Diffuse Large B-Cell Lymphoma: From Molecular Classification to Tailored Treatment Programs. • Disease heterogeneity
• Molecular classification, from COO to more recent models (Stuadt, Shipp, Dave)
• Standards of care
• Limitations of standards of care
• Evolving treatment options
• Targeting the molecular drivers
• The future of DLBCL care could look like this…..
2. Follicular Lymphoma: The Diminishing Role of Chemotherapy. • Disease heterogeneity
• Are we changing the natural history of the disease?
• The relevance of prognostic models
• Identifying the poorest risk subsets of patients
• Standards of care
• The evolving de-emphasis on chemotherapy
• How novel precision and targeted immunotherapies have become SOC
• The future of FL care could look like this….
3. Mantle Cell Lymphoma: Are We Moving from a One-Size-Fits-All Mentality Yet? • The spectrum of MCL biology
• The proliferation signature and its relationship to prognosis
• Standards of care
• Should we be tailoring care to the molecular prognostic features?
• Should transplant be considered a standard of care in eligible patients?
• Techniques for diagnosis and strategies for treating minimal residual disease
• The role of novel drugs in MCL
• The future: re-configuring novel and traditional chemotherapy to create new standards of care.
• The future of MCL care could look like this….
4. Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma and Waldenstroms Macroglobulinemia. • Putting the complex group of diseases in clear focus
• Distinguishing the molecular drivers among these entities
• Defining standards of care
• Emerging new drugs and how they are impacting natural history
• The future of care could look like this…..
5. The Peripheral T-Cell Lymphoma: Are We Turning the Corner by Shifting Our Focus to a Less Chemotherapy Predicated Paradigms? • Heterogeneity and rarity: a challenging combination in advancing care
• The molecular drivers of PTCL
• Standards of care
• A time of bounty: many new drugs coming along in PTCL
• Novel drug combinations: Could they form the basis of new treatment platforms?
• Is there a role for transplant in PTCL
• The future of PTCL care could look like this….
6. The Post-Transplant Lymphoproliferative Disorders. • Defining the scope of diseases
• What puts patients at risk of PTLD
• The role of EBV in driving PTLD development
• Preemptive strategies to reduce the risk of PTLD
• Standards of care
• The challenges of managing infectious risk of treatment
• Development of new regimens de-emphasizing the role of chemotherapy
7. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. • Defining the scope of diseases
• The importance of molecular prognostication
• Standards of care
• Is there any role for chemotherapy in managing CLL any more
• The spectrum of new drugs
• Reconfiguring novel therapies to create new standards of care
• The importance of MRD and its role in time-limited therapy
8. CAR-T Therapies: The Limitation and Potential Applications. • Understanding CAR-T biology
• Diseases carrying an approval for CAR-T
• The next wave of approvals will likely include….
• Managing the major toxicities of CAR-T
• Bridging patients to CAR-T therapies: a MAJOR AREA OF NEED
• The future of CAR-T care could look like this……
9. The Cutaneous T-cell Lymphoma (CTCL). • The spectrum of CTCL
• The principles of sound CTCL care
• Standards of care
• The plethora of drugs active in CTCL
• The future of CTCL care could look like this…..
10. Molecular Testing and How it Will Influence Lymphoma Care. • The biological spectrum of molecular testing
• Presently available technologies
• Interpreting data from patient genotyping
• Examples of how molecular genotyping might influence treatment decision making
Conclusion: Final Thoughts. Owen A. O'Connor and Francesca Montanari.
Participants
1. Thomas Matthew Habermann Division of Hematology, Mayo Clinic, Rochester, MN, USA.
2. Pier Luigi Zinzani and Beatrice Casadei Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
3. Francesco Bertoni Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Bellinzona, Switzerland.
4. Jennifer K. Lue Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USA.
5. Grzegorz S. Nowakowski Division of Hematology, Mayo Clinic, Rochester, MN, USA.
6. Helen Ma Division of Hematology and Oncology, University of California Irvine, CA, USA.
7. Enrica Marchi Division of Hematology-Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
8. Richard R. Furman New York Presbyterian Hospital, New York, United States.
9. Maria Cristina Cox Azienda Ospedaliera Sant'Andrea, Rome, Italy.
10. Guido Bocci Università di Pisa, Pisa, Italy.
11. Craig Portell Division of Hematology-Oncology, University of Virginia, Charlottesville, VA, USA.
12. Michael Williams Division of Hematology-Oncology, University of Virginia, Charlottesville, VA, USA.
13. Jeremy Abramson Dana Farber/Harvard Cancer Center, Boston, USA.
14. Ayumi Fujimoto and Ritsuro Suzuki Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
The list is arranged in no particular order and being updated.
Journal of Cancer Metastasis and Treatment
